Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07140380 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Controlled Study
A Phase 2 study of Dry Eye Disease, sponsored by IVIEW Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07140380: Active Phase 2 study of Dry Eye Disease, sponsored by IVIEW Therapeutics.
NCT07140380 is a Phase 2 study of Dry Eye Disease that is active but no longer recruiting, run by IVIEW Therapeutics. The registered enrollment target is 30 participants, below the 254-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07140380, a Phase 2 study of Dry Eye Disease, is active but no longer recruiting, sponsored by IVIEW Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Double-masked two period controlled trial of three eyelid wipe dosing techniques
Primary Outcome
Mean change from baseline in Unanesthetized Schirmer score
Conditions Studied
Interventions
- DRUG IVW-1001 Ophthalmic Eyelid Wipe
Study Locations (1)
California
- Eye Research Foundation - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-08-20 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
What the registry record for NCT07140380 still lists
NCT07140380 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 254-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 1 intervention - of which IVW-1001 Ophthalmic Eyelid Wipe is the first listed.
NCT07140380 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07140380 about?
NCT07140380 is a clinical study titled "Phase 2b Controlled Study". Double-masked two period controlled trial of three eyelid wipe dosing techniques
What is the current status of trial NCT07140380?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-08-20. Estimated completion is 2025-12-31.
What conditions does trial NCT07140380 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT07140380?
The interventions under investigation include: IVW-1001 Ophthalmic Eyelid Wipe (DRUG).
Who is sponsoring clinical trial NCT07140380?
This trial is sponsored by IVIEW Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07140380 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07140380's enrollment target sits among peer trials
30 32nd of 33 higher than 1 of 33 other Dry Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
RECRUITING · Phase 2
-
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
RECRUITING · Phase 2
-
A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease
ACTIVE NOT RECRUITING · Phase 2
-
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
COMPLETED · Phase 2
-
A Study of TL-925 as a Treatment for Dry Eye Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI